Study finds AI chatbot significantly improve symptoms for those suffering from major depressive disorder (MDD), generalized ...

Solriamfetol is a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT 1A agonist. It is currently approved under the brand name Sunosi ® to improve ...

A generative AI–powered therapy chatbot is linked to significant reductions in symptoms of depression, anxiety, and eating ...

India's National Mental Health Survey, mood disorders, major depressive disorder, bipolar disorder, genetic factors, environmental triggers, and treatment options.

A week after reporting a successful phase 3 trial of Sunosi (solriamfetol) in patients with attention-deficit/hyperactivity ...

Everyone experiences occasional ups and downs. However, dramatic mood swings and emotional instability that disrupt relationships, work or school and daily living could signal something more: ...

It was a busy week in the biotech sector, marked by significant regulatory and pipeline updates. Among these, shares of Corcept Therapeutics Incorporated CORT skyrocketed after a late-stage study met ...

Scientists at the National Center for Supercomputing Applications and the University of Illinois College of Medicine Peoria (UICOMP) were authors of a research paper published in the Journal of ...

Dynamic interpersonal therapy (DIT) is a short-term psychodynamic psychotherapy that has been shown to effectively reduce depressive symptoms in patients with major depressive disorder (MDD). In DIT, ...

Cigna's Evernorth unit is expanding coverage for Neuronetics' therapy for depression to adolescents. | Cigna's Evernorth unit ...

disorders, today announced results of the PARADIGM Phase 3 proof-of-concept trial of solriamfetol in major depressive disorder (MDD) with and without severe excessive daytime sleepiness (EDS).